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Summary Human T-lymphotropic virus type 1 (HTLV-1) carriers are known to develop
pulmonary complications characterized by T-lymphocytic alveolitis. The aim of this
study was to determine the profile and role of soluble Fas (sFas) and sFas ligand
(sFasL) in the lung of asymptomatic HTLV-1 carriers. We measured sFas and sFasL
levels in serum and bronchoalveolar lavage fluid (BALF) of 16 seropositive
asymptomatic HTLV-I carriers and 32 healthy subjects. The serum levels of both sFas
and sFasL were significantly higher in HTLV-I carriers than in the control. In BALF, the
percentage of lymphocytes and CD4 positive T-cells, and the levels of sFasL were also
significantly higher in asymptomatic carriers than the control, but there were no
significant differences in sFas levels between the two groups. There was a significant
correlation between BALF sFasL levels and serum sFasL levels and percentage of CD4
positive T-cells in BALF. Our results suggest that the increased levels of sFasL in the
lung of asymptomatic HTLV-I carriers are associated with accumulation of CD4 positive
T-cells, and that resistance to apoptosis in HTLV-1 infected T-cells and overproduction
of sFasL could contribute to T-lymphocytic alveolitis by down-regulating Fas–FasL
mediated apoptosis.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Human T-lymphotropic virus type 1 (HTLV-1) is a
retrovirus that causes adult T-cell leukemia (ATL)1,2
and is also associated with several non-malignant
disorders such as HTLV-1 associated myelopathy/
tropical spastic paraparesis (HAM/TSP),3,4 HTLV-1
uveitis (HAU),5 and HTLV-1 associated arthropathy.6
With regard to pulmonary involvement in HTLV-1
infection, patients with HAM/TSP and HAU frequently
exhibit pulmonary complications characterized by T-
lymphocytic alveolitis.7,8 Maruyama and coworkers9
also reported a strong association between bronch-
oalveolar disorders and patients with HTLV-1 infec-
tion, even healthy carriers of HTLV-1, and have
proposed the term HTLV-1-associated bronchopneu-
monopathy for these pathogenic conditions.
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Fas, a member of the tumor necrosis factor (TNF)
receptor family10, was originally described as a cell
surface membrane protein (mFas), but a soluble
Fas (sFas) in serum that lacks the transmembrane
domain due to alternative splicing has been
isolated.11 sFas blocks apoptosis by inhibiting the
binding of Fas ligand (FasL) to Fas on the cell
membrane.12 FasL, a 40-kDa type membrane
protein belonging to the TNF family,13 induces
apoptosis by binding to Fas receptor. FasL is
predominantly expressed on the cell surface mem-
brane (mFasL) in activated T-cells and natural killer
cells,14 whereas Fas is expressed in various cells
and tissues. FasL is converted to a soluble
formFsoluble Fas ligand (sFasL)Fby the action
of a matrix metalloproteinase-like enzyme.15 The
recent studies have revealed that the human sFasL
did not kill Fas-expressing leukemic T-cell line
Jurkat, lymphoma cells and primary mouse hepa-
tocytes.15–17 Soluble murine FasL also loses the
ability to induce apoptosis and inhibits membrane
FasL-induced cytotoxicity.18 Furthermore, high le-
vels of sFasL in the serum of the cancer patients are
associated with poor prognosis.19–21 These findings
suggest that sFasL could block cell apoptosis by the
immune system. In patients infected with HTLV-1,
serum and cerebrospinal fluid (CSF) levels of sFas
and sFasL have already been reported. In these
studies, high levels of sFas were found in sera of
HAM/TSP patients22,23 and high levels of sFasL were
also noted in sera and CSF samples from HAM/TSP
and ATL patients.24 These studies suggest that sFasL
may contribute to the inflammatory process and
subsequent tissue damage in patients infected with
HTLV-I.
The present study was designed to clarify
the involvement of sFas and sFasL in lung
inflammation of HTLV-1 carriers. For this
purpose, we compared the levels of sFas and
sFasL in serum and bronchoalveolar lavage fluid
(BALF) of asymptomatic HTLV-1 carriers and healthy
subjects.
Materials and methods
Study population
The study population consisted of 16 seropositive
asymptomatic HTLV-1 carriers (10 males and six
females, aged 54711 years, mean7SD) who were
referred to our hospital and performed bronchoal-
veolar lavage between September 1992 and De-
cember 1998, and 32 healthy subjects (25 males
and seven females, aged 2474 years). Seven HTLV-
1 carriers and three controls were smokers.
Seropositivity was determined using both the
particle agglutination and indirect immunofluores-
cence tests. All HTLV-I carriers had no other
viral infections, no other HTLV-1 associated
diseases and normal chest radiographic findings.
All healthy subjects were HTLV-1 seronegative,
also free of any viral infection and normal
chest radiographic findings. Informed consent was
obtained from all carriers and healthy subjects
prior to the commencement of the study, and the
human experimentation guidelines of Nagasaki
University were followed in conducting clinical
research.
Bronchoalveolar lavage and cell preparations
Bronchoalveolar lavage was performed as described
previously.25 The patient was premedicated intra-
muscularly with atropine (0.5mg). After local
anesthesia with 4% lidocaine, a flexible broncho-
scope (BF P200, Olympus, Tokyo) was wedged into a
subsegment of the right middle lobe for lavage. A
50-ml sterile physiological saline solution at body
temperature was instilled through the broncho-
scope and the fluid was immediately retrieved by
gentle suction using a sterile syringe. Saline
instillation was performed four times. The col-
lected lavage fluid was passed through two sheets
of gauze and centrifuged at 400 g for 10min at
41C and the supernatant was stored at –801C until
use. After washing twice with phosphate buffered
saline solution, cells were suspended with 10% heat
inactivated fetal calf serum (FCS) and counted
using a hemocytometer. An aliquot was then
adjusted to 2 105 cells/ml and 0.2ml sample of
each cell suspension was spun down onto a glass
slide at 160 g for 2min using a cytocentrifuge
(cytospin 2, Shandon Instruments, PA). The slides
were dried, fixed, and then stained using the May–
Giemsa method. Two hundred cells were identified
under the photomicroscope. The remaining cells
were resuspended in RPMI-1640 medium (Gibco,
Paisley, Scotland) supplemented with 10% FCS, and
incubated in plastic dishes for 60min at 371C in
humidified 5% CO2–air environment. More than 90%
of non-adherent cells collected for flow cytometric
analysis were viable as determined by the trypan
blue exclusion test.
Monoclonal antibodies
Fluorescein isothiocyanate (FITC)-conjugated anti-
CD25 (interleukin-2 receptor (IL-2R)-a) antibody
and phycoerythrin (PE)-conjugated anti-CD3, CD4,
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CD8 antibodies were used in the study. Mouse IgG1
and IgG2a conjugated with FITC or PE (Becton
Dickinson, San Jose, CA) were used to determine
the borderline between stained and unstained cells
in flow cytometric analysis.
Measurement of sFas and sFasL by ELISA
Serum and BALF concentrations of sFas and sFasL
were measured by a sandwich enzyme-linked
immunosorbent assay (ELISA) kit (sFas, sFasL ELISA
kit, MBL, Nagoya, Japan). Briefly, samples to be
measured or standards were incubated in wells
coated with anti-Fas polyclonal antibody or anti-
FasL monoclonal antibody. After washing, a perox-
idase-conjugated anti-Fas monoclonal antibody or
anti-FasL monoclonal antibody was added to the
well. After incubation the wells were washed, then
the peroxidase substrate was mixed with the
chromogen and allowed to incubate for an addi-
tional period of time. An acid solution was then
added to each well to terminate the enzymatic
reaction and stabilize the developed color. The
optical density of each well was measured at
450 nm using a microplate reader. The concentra-
tions of sFas and sFasL were determined from the
respective calibration curves constructed using
reference standards. Lower limits of detection
were 8 pg/ml for sFas and 6 pg/ml for sFasL.
Statistical analysis
All values were expressed as mean7SD. The Mann–
Whitney U-test was used to compare differences
between unpaired samples. Correlations between
parameters were determined by Spearman’s rank
correlation coefficient. P values less than 0.05 were
regarded as significant.
Results
Characteristics of BALF cells
The characteristics of BALF cells are summarized in
Table 1. Carriers had a significant higher total
number of leukocytes in BALF and higher percen-
tages of lymphocytes, CD3þ , and CD4þ T-cells,
and CD4/CD8 ratio compared with healthy
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Table 1 BALF cell findings in control subjects and asymptomatic HTLV-1 carriers.
Healthy subjects Asymptomatic carriers
Total cells 105/ml 1.5571.09 2.2670.97n
Macrophages (%) 87.476.9 77.4713.2w
Lymphocytes (%) 9.876.6 19.6713.4w
Neutrophils (%) 2.273.9 2.973.9
Eosinophils (%) 0.671.2 0.370.6
CD3þ (%) 78.5711.9 87.678.3n
CD4þ (%) 35.0712.2 55.3711.8n
CD8þ (%) 42.3713.4 35.6713.4
CD4/CD8 0.9970.57 2.0171.40n
CD3þCD25þ (%) 5.674.9 12.0713.2
Values are expressed as mean7SD.
nPo0:01; compared with healthy subjects.
wPo0:05; compared with healthy subjects.
(a) (b)
n
g/
m
l
0
1
2
3
pg
/m
l
0
20
40
60
80
100
p<0.01
HealthyHealthy Carriers Carriers
Serum sFas BALF sFas
Figure 1 Soluble Fas (sFas) concentrations in serum (a),
and BALF (b) of healthy subjects and asymptomatic
carriers (ACs). The box and whisker plots represent 25–
75th percent of results inside the box, the median is
indicated by the horizontal bar across the box, and the
whiskers on each box represent the 10–90th percentiles.
The serum sFas concentrations of ACs are significantly
higher than those of healthy subjects.
sFas and sFasL in serum and BALF of HTLV-1 carriers 215
subjects. However, there was no significant differ-
ence in the percentage of CD3þCD25þ T-cells
between the two groups.
sFas and sFasL concentrations in serum and
BALF
The mean serum sFas concentration in asympto-
matic HTLV-I carriers (2.270.4 ng/ml) was signifi-
cantly higher than in healthy subjects (1.770.3 ng/
ml, P ¼ 0:003; Fig. 1a). There was no significant
difference in BALF concentrations of sFas between
the two groups (control: 73.9716.2 pg/ml, car-
riers: 65.1722.0 pg/ml, P ¼ 0:06; Fig. 1b). Both the
serum and BALF concentrations of sFasL were
significantly higher in HTLV-I carriers (serum:
98.9721.1 pg/ml, BALF: 23.977.1 pg/ml) than in
healthy subjects (serum: 66.7732.6 pg/ml, P ¼
0:006; BALF: 14.878.8 pg/ml, P ¼ 0:002; Fig. 2a
and b).
Correlations between serum and BALF
concentrations of sFas or sFasL
There was no correlation between serum and BALF
sFas concentrations (Fig. 3a). But serum sFasL
concentrations correlated significantly with BALF
sFasL concentrations (Fig. 3b) in the control and
asymptomatic carriers. In addition, there was
significant correlation between serum sFas and
serum sFasL concentrations (r ¼ 0:554; Po0:001;
data not shown) and no correlation between BALF
sFas and BALF sFasL concentrations (r ¼ 0:039; P ¼
0:828; data not shown).
Correlations between BALF sFasL
concentrations and BALF cells
BALF sFasL concentrations correlated with the
percentage of CD4þ T-cells in BALF of healthy
subjects and carriers (Fig. 4). However, there was
no significant correlation between BALF sFas con-
centrations and BALF cells.
ARTICLE IN PRESS
(a) (b)
0
20
40
60
80
100
120
140
pg
/m
l
pg
/m
l
0
10
20
30
40
p<0.01
p<0.01
Healthy Carriers Healthy Carriers
Serum sFasL BALF sFasL
Figure 2 sFasL concentrations in serum (a), and BALF (b)
of healthy subjects and asymptomatic carriers (ACs). The
serum and BALF sFasL concentrations of ACs are
significantly higher than those of healthy subjects.
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Figure 3 Correlation between serum soluble Fas (sFas) and BALF sFas (a), and serum sFasL and BALF sFasL
concentrations (b) in healthy subjects and asymptomatic carriers. BALF sFasL concentrations correlate significantly
with serum sFasL concentrations.
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Figure 4 Correlation between BALF sFasL concentra-
tions and the percentage of CD4þ lymphocytes in BALF
with healthy subjects and asymptomatic carriers. BALF
sFasL concentrations correlate significantly with the
percentage of CD4þ lymphocytes.
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Discussion
The major findings of the present study were the
presence of high concentrations of sFasL in BALF,
and sFas and sFasL concentrations in serum of
asymptomatic HTLV-I carriers. Several studies have
shown that HAM/TSP is frequently associated with
T-lymphocytic alveolitis.7,8 A similar pulmonary
involvement has also been observed in asympto-
matic carriers.9 We previously demonstrated the
presence of high percentages of CD3þCD25þ T-
cells, i.e., activated T-cells, in BALF of HAM/TSP
patients and asymptomatic carriers.25 In addition,
Kawakami and co-workers26 reported that the
histopathological changes in the lung tissues of
HTLV-1 transgenic mice showed inflammatory
changes with bronchoalveolar lymphocytosis that
resembled the histopathological findings observed
in HTLV-1-infected patients. We have also reported
that HTLV-1 tax mRNA, encoding the transcriptional
transactivator Tax, was more frequently detected
in BALF cells compared with peripheral blood
mononuclear cells and was closely associated with
infiltration of activated T-lymphocytes in lung
tissue.27 Furthermore, the expression of tax mRNA
was detected in BALF cells of all HAM/TSP patients
and even eight of 17 asymptomatic carries. It is
well known that Tax plays a crucial role in the
inflammatory response in the lungs of HTLV-1-
infected individuals by upregulating the viral
promoter and expression of various cellular
genes.28–30 Tax can also induce the expression of
the FasL gene in CD4þ T-cell line.31 Therefore, our
present findings demonstrating the presence of
high concentrations of sFasL in the serum and BALF
of HTLV-1 carriers and a significant correlation
between sFasL concentrations and the percentage
of CD4 positive T-cells in BALF are not unexpected.
It has been shown that human T-cell lines expres-
sing Tax were resistant to apoptosis signals trig-
gered through Fas receptor, and T-cells derived
from patients with TSP/HAM and from transgenic
mice carrying the env-pX region of HTLV-1 in-
creased resistance to Fas apoptosis.32 It has also
been reported that the inactivated supernatants of
some HTLV-1-positive T-cell lines can transfer
resistance to apoptosis to uninfected cells.33 These
data suggests that HTLV-1 infected T-cells are
resistant to apoptosis and increased in lung tissue,
and thus secretion, such as sFasL, from HTLV-1
infected cells inhibits apoptosis to uninfected
T-lymphocytes. Together with our present results,
T-lymphocytic alveolitis by down-regulating Fas–
FasL mediated apoptosis may be observed in lungs
of asymptomatic carriers, although the additional
clinical and in vitro studies will need to refute our
hypothesis. Human immunodeficiency virus (HIV),
which is the same kind of human retroviral
infection, also induces the expression of FasL. By
upregulating FasL, the infected cells evade apop-
tosis induced by cytotoxic T-lymphocytes.34 How-
ever, asymptomatic infected individuals do not
show the lymphocytic alveolitis in the lung,35 so it
would be interesting to clear what are the
differences in T-cell alveolitis and in the role of
the Fas/FasL system between HTLV-1 and HIV
infections.
In the present study, the serum concentrations of
sFas in carriers were also significantly higher than
in healthy subjects. Previous studies have shown
significantly higher mFas positive rate on T-cells
and serum sFas concentrations in HAM/TSP and ATL
patients compared with healthy subjects. Kamihira
et al.23 reported a positive correlation between
sFas and soluble interleukin-2 receptor (sIL-2R) in
serum of HTLV-1 infected patients. They also
demonstrated that serum sFas concentrations
significantly correlated with various clinical para-
meters, such as serum lactic dehydrogenase activ-
ity, tumor burden, hypercalcemia and prognosis in
ATL,36 and suggested that sFas and sIL-2R are of the
same origin, and were possibly derived from
activated-T-cells or leukemic-T-cells. In the present
study, the percentage of CD3þCD25þ (IL-2R), a
marker of activated-T-cells, in peripheral blood of
carriers was higher than in healthy subjects (data
not shown). These results suggest that serum sFas
derived from activated-T-cells and/or HTLV-1 in-
fected cells, may block apoptotic cell death by
inhibiting the binding of mFasL to mFas and that
HTLV-1 infected cells may be persistently present in
HTLV-I infected patients. Tax also activates
a number of cellular genes, including IL-2 and
IL-2Ra.37 IL-2 is known to upregulate anti-apoptotic
members of the BCL-2 family. IL-2 also promotes
Fas-dependent activation-induced cell death by
upregulating Fas and FasL.38 Thus, the role of IL-2
in apoptosis is now controversial, but it is possible
that these other cytokines also regulate the
lymphocyte apoptosis in the lung of HTLV-1 carriers.
We found no significant difference in BALF sFas
concentrations between carriers and healthy sub-
jects, and no correlations between BALF sFas
concentrations and BALF cells. Kuwano et al.39,40
demonstrated that the expression of mFas was
upregulated in bronchoalveolar and alveolar
epithelial cells in lung tissues from patients with
idiopathic pulmonary fibrosis (IPF) but sFas con-
centrations in BALF were not significantly higher in
IPF patients compared with control subjects and
did not correlate with the number of inflammatory
cells. These results indicate that the production of
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sFas concentrations in BALF may be derived from
not only lymphocytes but also other cells.
In our study, the mean age of the healthy controls
was considerably lower compared with the HTLV-1
carriers. Gupta have observed increased expres-
sions of Fas and FasL in T-cells from aging subjects
as compared with healthy young control.41 Seishi-
ma and colleagues have also reported that the
levels of sFas in serum were increased with aging.42
Therefore, it could be the reason why the serum
levels of sFas in the HTLV-1 carriers were higher
than those in the healthy controls in this study.
However, the serum levels of sFasL have been
reported to be decreased with aging,43 so our
findings demonstrating the higher levels of sFasL in
HTLV-1 carriers did not merely reflect the influence
of age.
In conclusion, we have demonstrated in the
present study the presence of elevated concentra-
tions of sFas and sFasL in serum and sFasL in BALF of
asymptomatic HTLV-I carriers relative to those of
healthy subjects. We also found a significant
correlation between the concentrations of sFasL
and percentage of CD4þ T-cells in BALF. Although
we have not directly demonstrated the correlation
between sFasL levels in BALF and the inhibition of
lymphocyte apoptosis, our findings speculate that
overproduction of sFasL in the lung of asympto-
matic HTLV-1 carriers perpetuates the inflamma-
tory condition and leads to T-lymphocytic alveolitis
by down-regulating Fas-mediated apoptosis.
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